Alpha Emitter Market Size, Share, Trends and Forecast by Type of Radionuclide, Medical Application, End User, and Region, 2025-2033

The global alpha emitter market size was valued at USD 1,834.48 Million in 2024. Looking forward, IMARC Group estimates the market to reach USD 12,040.20 Million by 2033, exhibiting a CAGR of 23.25% from 2025-2033. North America currently dominates the market, holding a market share of over 43.7% in 2024. Factors such as the increasing focus on targeted cancer treatments, along with the rising number of new nuclear-medicine-based product approvals, are bolstering the alpha emitter market share.

Alpha emitters are substances emitted by radioactive sources that decay after releasing alpha particles. They achieve appropriate biodistribution and associated dose distribution to achieve effective therapy without causing unacceptable acute or long-term side effects. With their exceptionally high cell-killing rates, alpha particles are more destructive to tumor cells than beta particles when used in medical procedures. Consequently, they cause less damage to adjacent normal tissues. Radium, lead and bismuth are some of the radionuclides used in the treatment process. The short range and high linear energy transfer (LET) of alpha particles have made them remarkably appealing to medical research, particularly as a viable treatment method for cancer. There are numerous types of cancer that can be treated with alpha emitters, including ovarian cancer, pancreatic cancer, lymphoma, and melanoma.

Alpha Emitter Market Trends:

The market is majorly driven by extensive and high-end research and development (R&D) activities being conducted in cancer treatment. This can be attributed to the growing awareness regarding the cell-killing abilities of targeted alpha emitters. In line with this, the rising prevalence of various types of cancer among the masses is providing an impetus to the market. Also, the increasing geriatric population that is susceptible to develop numerous cardiac and cancer ailments is creating a positive outlook for the market. Moreover, the rising adoption of targeted anticancer or alpha therapy (TAT) in healthcare facilities is impacting the market positively. The market is further propelled by continual technological advancements and the growing number of new nuclear-medicine-based product approvals. Some of the other factors contributing to the market include rapid urbanization, continual improvements in healthcare infrastructure, rising medical expenditure and inflating disposable income levels of the individuals.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global alpha emitter market, along with forecast at the global, regional, and country levels from 2025-2033. The market has been categorized based on type of radionuclide, medical application, and end user.

Breakup by Type of Radionuclide:

• Astatine
• Radium
• Actinium
• Lead
• Bismuth
• Others

Breakup by Medical Application:

• Prostate Cancer
• Bone Metastasis
• Ovarian Cancer
• Pancreatic Cancer
• Endocrine Tumors
• Others

Breakup by End User:

• Hospitals
• Medical Research Institutions
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Actinium Pharmaceuticals Inc., Alpha Tau Medical Ltd., Bayer AG, Fusion Pharmaceuticals, IBA RadioPharma Solutions and RadioMedix Inc.

Key Questions Answered in This Report

1.How big is the alpha emitter market?

2.What is the future outlook of alpha emitter market?

3.What are the key factors driving the alpha emitter market?

4.Which region accounts for the largest alpha emitter market share?

5.Which are the leading companies in the global alpha emitter market?
Show more